Literature DB >> 6851405

Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina.

R A Morrison, U W Wiegand, E Jähnchen, D Höhmann, H Bechtold, T Meinertz, H L Fung.   

Abstract

Isosorbide dinitrate (ISDN) kinetics and dynamics were examined after various routes of administration for angina. Given intravenously, ISDN kinetics were apparently linear over the range of infusion rate (0.083 and 0.133 mg/min) and duration (15 min and 1 and 2 hr) studied. Mean +/- SD systemic clearance of ISDN was 3.4 +/- 1.4 l/min and volume of distribution (VdSS or Vdarea) about 100 l. These data are consistent with the presence of extensive extrahepatic metabolism. In six patients, sublingual ISDN (5 mg) was also given and mean bioavailability of 59% (19% to 93%) for this route was determined. For this group, sublingual absorption of intact ISDN was incomplete and variable. The presence of a longer disappearance t 1/2 after sublingual dosing suggested that the input process may be rate limiting. After percutaneous application of a topical formulation (100 mg over an area of 400 cm2), steady-state plasma concentrations at about 7 ng/ml were maintained from 6 to 24 hr. The bioavailability of the topical application was estimated at 30%. At the doses given, intravenous ISDN had no apparent effect on heart rate but induced significant reduction in standing systolic blood pressure. The effect vs the ISDN concentration profile was described by a hysteresis loop, indicating that changes in blood pressure response lag behind changes in plasma ISDN concentration. After intravenous dosing, peak plasma ISDN concentration and peak effect (maximum change in standing systolic blood pressure). At the doses used, both sublingual and percutaneous ISDN induced less distinct circulatory changes than the intravenous infusion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6851405     DOI: 10.1038/clpt.1983.102

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 3.  Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics.

Authors:  Fereidoon Daryaee; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2019-04-28       Impact factor: 8.822

4.  Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.

Authors:  Y Santoni; A Iliadis; J P Cano; R Luccioni; Y Frances
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

Review 5.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 6.  Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates.

Authors:  U Thadani; T Whitsett
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

7.  Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.

Authors:  U Abshagen; G Betzien; R Endele; B Kaufmann; G Neugebauer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.

Authors:  D Vogt; D Trenk; R Bonn; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.